Special Issue- Coverage for Benign or Premalignant Skin Lesion Removal by Blue Cross and Blue Shield of Florida, Inc.
. Coverage for Benign or Premalignant Skin Lesion Removal 
! Background Medicare B ofFlorida has developed a medical policy for these services as well as services for the removal of benign, either by shaving or excision (procedure codes 11300 
through 11446); the destruction of benign facial or, premalignant skin lesions in any location (p,ocedure codes 17000 through 17002) destruction by any method of 
complicated benign or premalignant lesions (procedure code 1701 O); destruction by any method beni~ or premalignant lesion on any area other than face (17101 through 
17105); and the destruction by any method offlat warts or molluscum contagiosum and milia ( 17110). 
Covered Conditions and/or Diagnoses 
M:dicare B will consider the destruction of a benign or premalignant skin 
· lesion medically necessary under the following circumstances: 
• When the patient has multiple actinic keratoses and has self-administered 2% 
to 5% Fluorouracil topical cream for two to four weeks an.d. the actinic 
keratoses have not responded to this treatment one to two months following 
treatment•, .or 
It should be noted that the natural response to fluorouracit (Efudex) is 
erythema, usually followed by vesiculation, desquamation, erosion and 
reepitheliatization. Therefore, during 8.!}d immedicately following 
fluorouracil treatment these signs and symptoms would be considered 
part of the healing process and would not be considered as meeting the 
criteria for removal. There are contraindications for topical 
fluorouracil which include pregnancy, use on mucous membranes, use 
on mouth, and use around eyes or on nose. If after two months 
following treatment with fluorouracit, the actinic keratoses have not 
responded, they may be removed or destroyed. 
• When a patient presents with an actinic keratosis that has changed in size, has 
developed erythema, has thickened, has ulcerated, has eroded, has developed 
changes at the tumor margins, has become markedly hyperkeratotic, in which 
pain has developed and/or a cutaneous horn has developed; 
• When the patient presents with an actinic chcilitis (actinic keratosis of the 
lower lip) or an actinic keratosis on the upper lip; 
. • When the patient presents with an actinic conjunctivae (actinic keratosis of the 
conjunctiva); 
· • When the patient presents with an actinic keratosis on the nose, ear or eyelid; 
: • When the patient presents with a actinic keratosis and has a history of one of 
the following: 
- chronic immunosuppression such as that associated with organ transplan-
tation, particularly renal transplantation, and other disease processes such 
as Human Immunodeficiency Virus (HIV) or Acquired Immune Defi-
ciency Syndrome (AIDS) and/or chronic lymphocytic leukemia or 
lymphoma; 
treatment of psoriasis with psolaren-ultraviolet A (PUV A) therapy; 





























CPT coding is based on the type of lesion (benign or prernalignant), 
method of destruction or removal, and the number of lesions removed 
for any of the procedure codes within the following ranges: 11300-
11313; 11400-11446; 17000-17002; or 17100-17110. 
If a lesion is destroyed or removed for any reason or for any cir-
cumstance other than ones listed in this article, the procedure is 
considered medically unnecessary and is, therefore, not reimbursur-
able by Medicare. 
When the patient is seen in the office for purposes of prescribing 
fluorouracil and providing instruction on how to use this medica-
tion, the appropriate level of Evaluation and Management service 
may be billed. 
Procedure code 17000 may only be billed once per day. Procedure 
code 17001 may be billed no more than two times in one day because 
the descriptor reads "2nd and 3rd lesion, each lesion". It is not appro-
priate to use the modifier -76 (repeat procedure) with these codes. 
Procedure codes 17100 through 17104 are to be billed in a similar 
manner. The first lesion should be billed utilizing procedure code 
17100. If a second lesion is removed, it should be billed utilizing proce-
dure code 17101. If three to fifteen lesions are removed on the same 
day as the first and second, procedure code 17102 may also be billed. 
Procedure code 17104 is used when fifteen or more lesions are re-
moved. It is not appropriate to bill this code.with 17100, 17101, or 
17102 .o.r. to bill with the modifier -76 . 
Coverage for Benign or Premalignant Skin Lesion Removal (con't) 
Covered Conditions and/or Piagnoses (con't) 
- previous treatment of a biopsy-proven Squamous Cell Carcinoma (SCC). 
. • When a patient presents with an arsenical keratosis (due to arsenic exposure); 
i • When a patient presents with a keratosis and has a history of significant exposure to therapeutic 
1 or occupational radiation therapy (chronic radiation kertosis). 
I 
1 
• When a patient presents with a keratosis which arises from an old scar (chronic cicatrix 
I 
1 keratosis). 
If none of the aforementioned conditions exist, Medicare B of Florida would consider 
the removal of an actinic keratosis as medically unnecessary and, therefore, not reim-
bursable by Medicare. 
In .'lddition, chemical peels of the face, even in the presence of actinic keratoses, are 
i considered medically unnecessary in nature because the technique is used to Improve the 
1!' appearance of photodamaged skin, and is, therefore, not reimbursable by Medicare. 
. The total number of services billed utilizing procedure codes 17000, 17001, .a.n.d.17002 
! which exceed the number that would be considered medically necessary and reasonable 
i according to established parameters will be reviewed on a prepayment basis using the cri-
: teria above and may be denied as not medically necessary or reasonable. 
: Generally, the removal of benign lesions such as seborrheic keratoses, sebaceous cysts, and 
, warts are done for cosmetic reasons, however, in .care instances it may be necessary to remove 
: these types of lesions. Medicare B of Florida will consider the removal of these lesions as 
medically necessary for any of the following reasons: 
• the lesion is in an area such as the neck or waist and is constantly irritated and/or is located in 
an anatomical location of recurrent trauma and that such trauma has in fact occurred; 
. • the lesion obstructs an orifice or clinically obstructs vision (this would include any lesion); 
• the patient presents with condylomata acuminta (venereal warts) and/or is immunosuppressed; 
and/or, 
I • plantar warts or other lesions on the sole of the foot which impede the patient's ability to 
ambulate or which meet any of the aforerncntionr:d criteria. 
If the aforementioned signs and symptoms are not present, further treatment would 
; be considered medically unnecessary in nature and, therefore, not reimbursable by Medi-
; care. 
Destruction of benign or premalignant lesions that exceed utilization parameters as 
• determined by our analysis of frequency data for beneficiaries may be reviewed for medi-




If the patient presents with multiple actinic keratoses, the self-administration of topical 
2% to 5% fluorouracil cream or solution for a period of no less than two weeks and unre-
sponsiveness to the medication after two months should be documented. If the patient has 
a condition in which fluorouracil is contraindicated such as pregnancy or actinic keratosis 
( es) around the eyes on the nose, on the mouth, or on mucous membranes, the physician's 
office/progress note should reflect this. The location of the lesion(s) should be docu-
mented as well. 
If the patient presents with an actinic keratosis(es) and its appearance has changed, i.e. 
size, erythema, thickening, ulceration, and/or erosion in the tumor or tumor margins m if 
the patient has developed pain within the lesion, this should be clearly documented in the 
physician's progress/office note to substantiate removal of the lesion. 
If the patient presents with an actinic cheilitis (actinic keratosis of the lower lip) or an 
actinic keratosis on the ear or conjunctiva, the exact location and a description of the le-
sion's appearance should be documented in the physician's progress/office note. 
If the patient presents with an actinic keratosis and has a history of chronic immuno-
suppression; treatment of psoriasis with PUV A therapy; xerodenna pigmentosum, disco id 
lupus erythematosus or albinism; and/or a previous treatment of a biopsy-proven SCC, this 
should clearly be documented in the physician's progress/office note. The approximate 
starting date and duration of radiation therapy or PUV A therapy should be documented, if 
applicable. In addition, the date of organ transplantation sho.uld be documented, if applica-
ble. Any other immunosuppressive disorder should be documented with the date or ap-
proximate date of diagnosis. 
Also, if the patient has had a previous biopsy-proven SCC or other skin malignancy, 
the location of that lesion, the date of removal, and a pathology report for the previous le-
sion, if available, should be documented. In addition, for the aforementioned condi-
tions/treatments, the exact location and a description of the lesion should be documented. 
For cicatrix keratoses, the location of the scar, the type of the scar, the approximate 
date the scar developed, and a description of the size, location and appearance of the lesion 
should be documented in the physicians' progress/office note. 
Although not required at this time, a photograph of the lesion with an indication of the 
size and location would be an excellent documentation tool for the size, location, and ap-
pearance of the lesion. If the physician is not able to take a photograph or make a sketch 
in his/her notes regarding size, location, and appearance of the lesion, a very clear descrip-
tion of the lesion must be included in the progress/office note. 
For those benign lesions that are located in areas which subject the lesion to con-
stant irritation and/or trauma and need to be removed because of constant or frequent 
traumatization, the exact location and size of the lesion and type of irritation and/or trauma 
should be documented in the physician's progress note/office note. 
In addition, to the above, the method of destruction or removal should be de-
scribed in the physician's progress/office note for any type of lesion destroyed or re-
moved. 
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